Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 11/20 | 0.51 |
| ▸ | SLC2A3 | P11169 | 11/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27248850 | 1.00 | SLC2A1 (0.51) | SLC2A1SLC2A3PTK2ROCK2ROCK1 | |
| SCHEMBL27248991 | 0.86 | SLC2A1 (0.49) | SLC2A1SLC2A3ROCK2ROCK1SYK | |
| SCHEMBL27248812 | 0.85 | SLC2A1 (0.57) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL27249049 | 0.85 | SLC2A1 (0.51) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL31173645 | 0.85 | SLC2A1 (0.51) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL27248597 | 0.83 | MEN1 (0.63) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL27249055 | 0.82 | ROCK2 (0.55) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL31173546 | 0.81 | SLC2A1 (0.49) | SLC2A1SLC2A3ROCK2ROCK1SYK | |
| SCHEMBL27248985 | 0.81 | SLC2A1 (0.49) | SLC2A1SLC2A3ROCK2ROCK1SYK | |
| SCHEMBL27248767 | 0.81 | SLC2A1 (0.51) | SLC2A1SLC2A3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | SLC2A1 2/4885SLC2A3 1/4885PTK2 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.